Ethical and scientific implications of the globalization of clinical research

New England Journal of Medicine

Volumn 360, Issue 8, 2009, Pages 816-

  Glickman, Seth W ^a,c   McHutchison, John G ^a,b   Peterson, Eric D ^a,b   Cairns, Charles B ^a,c   Harrington, Robert A ^a,b   Califf, Robert M ^a,b   Schulman, Kevin A ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; COST CONTROL; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG RESEARCH; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; GLOBAL CHANGE; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFORMED CONSENT; MEDICAL LITERATURE; METHODOLOGY; PRIORITY JOURNAL; RESEARCH ETHICS; RESEARCH SUBJECT; REVIEW; SOCIOECONOMICS; STRATEGIC PLANNING; UNITED STATES;

EID: 60849106348     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb0803929     Document Type: Article

References (62)

1. Osland JS. Broadening the debate: the pros and cons of globalization. J Manage Inq 2003;12:137-54.
2. Country classification: a short history. Washington, DC: The World Bank. (Accessed January 30, 2009, at http://go.worldbank.org/K2CKM78CC0.)
3. Getz KA. Global clinical trials activity in the details. Applied Clinical Trials. September 1, 2007. (Accessed January 30, 2009, at http:// appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/ articleDetail.jsp?id=453243.)
4. Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials. Nat Rev Drug Discov 2008;7:13-4.
5. Rehnquist J. The globalization of clinical trials: a growing challenge in protecting human subjects. Washington, DC: Department of Health and Human Services, 2001. (DHHS publication no. OEI-01-00-00190.)
6. Rowland C. Clinical trials seen shifting overseas. Int J Health Serv 2004;34:555-6.
7. Farkouh ME, Dangas G, Leon MB, et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J 2008;155:215-23.
8. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-407.
9. Truelove C. 21st Annual report: belt tightens on big pharma. Med Ad News 2007;26:4-7.
10. Garnier JP. Rebuilding the R&D engine in big pharma. Harv Bus Rev 2008;86:68-76.
11. Bailey W, Cruickshank C, Sharma N. Make your move: taking clinical trials to the best location. (Accessed January 30, 2009, at http://www.atkearney.com/ main.taf?p=5,1,1,116,3,1/.
12. Making the most of existing health workers. In: Working together for health: the World Health Report 2006. Geneva: World Health Organization, 2006:66-95. (Accessed January 30, 2009, at http://www.who.int/whr/2006/chapter4/ en/index.html.
13. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
14. Stough WG, Zannad F, Pitt B, et al. Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards. Am Heart J 2007; 154:232-8.
15. Rai S. Drug companies cut costs with foreign clinical trials. New York Times. February 24, 2005:C4.
16. Schmidt CW. Monitoring research overseas. Modern Drug Discovery 2001;4:25-6.
17. Nundy S, Gulhati CM. A new colonialism? Conducting clinical trials in India. N Engl J Med 2005;352:1633-6.
18. Yusuf S. Randomized clinical trials: slow death by a thousand unnecessary policies? CMAJ 2004;171:889-92.
19. Gershon D. From bench to bedside and back? Nature 2001;411:4-5.
20. Califf RM. Simple principles of clinical trials remain powerful. JAMA 2005;293:489-91.
21. Dilts DM, Sandler AB, Baker M, et al. Processes to activate phase III clinical trials in a cooperative oncology group: the case of Cancer and Leukemia Group B. J Clin Oncol 2006;24:4553-7.
22. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 2006;24:4545-52.
23. Yusuf S, Bosch J, Devereaux PJ, et al. Sensible guidelines for the conduct of large randomized trials. Clin Trials 2008;5:38-9.
24. Shuchman M. Commercializing clinical trials - risks and benefits of the CRO boom. N Engl J Med 2007;357:1365-8.
25. The Food and Drug Administration's oversight of clinical trials. Washington, DC: Department of Health and Human Services, 2007. (DHHS publication no. OEI-01-06-00160.
26. London L. Ethical oversight of public health research: can rules and IRBs make a difference in developing countries? Am J Public Health 2002;92:1079-84.
27. Killen J, Grady C, Folkers GK, Fauci AS. Ethics of clinical research in the developing world. Nat Rev Immunol 2002;2:210-5.
28. The ethics of clinical research in developing countries. London: Nuffield Council on Bioethics, 1999. (Accessed January 30, 2009, at http://www. nuffieldbioethics.org/fileLibrary/pdf/clinicaldiscuss1.pdf.
29. Hill Z, Tawiah-Agyemang C, Odei-Danso S, Kirkwood B. Informed consent in Ghana: what do participants really understand? J Med Ethics 2008;34:48-53.
30. Annas GJ, Grodin MA. Human rights and maternal-fetal HIV transmission prevention trials in Africa. Am J Public Health 1998;88:560-3.
31. Hutton JL. Ethics of medical research in developing countries: the role of international codes of conduct. Stat Methods Med Res 2000;9:185-206.
32. Angell M. The ethics of clinical research in the Third World. N Engl J Med 1997;337:847-9.
33. Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical trials in developing countries. N Engl J Med 2001;345:139-42.
34. Srinivasan S, Loff B. Medical research in India. Lancet 2006;367:1962-4.
35. Jack A. New lease on life? The ethics of offshoring clinical trials. Financial Times. January 28, 2008:58.
36. Jayaraman KS. Indian regulations fail to monitor growing stem cell use in clinics. Nature 2005;434:259.
37. Magotra R. The controversy of drug-eluting cardiac stents. Indian J Med Ethics 2006;3:25-6.
38. We get it free and charge you. Indian J Med Ethics 2000; 8:108-10.
39. Hyder AA, Wali SA, Khan AN, Teoh NB, Kass NE, Dawson L. Ethical review of research: a perspective from developing country researchers. J Med Ethics 2004;30:68-72.
40. Zhang D, Yin P, Freemantle N, Jordan R, Zhong N, Cheng KK. An assessment of the quality of randomized controlled trials conducted in China. Trials 2008;9:22.
41. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. (Accessed January 30, 2009, at http://www.icmje.org/.
42. Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med 2002;347:1335-41.
43. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability. N Engl J Med 2001;345:825-6.
44. Abbas EE. Industry-sponsored research in developing countries. Contemp Clin Trials 2007;28:677-83.
45. Duley L, Antman K, Arena J. Specific barriers to the conduct of randomized trials. Clin Trials 2008;5:40-8.
46. Council for International Organizations of Medical Sciences (CIOMS). International ethical guidelines for biomedical research involving human subjects. (Accessed January 30, 2009, at http://www.cioms.ch/frame-guidelines- no-2002.htm.
47. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. (Accessed January 30, 2009, at http://www.wma.net/e/policy/pdf/17c.pdf.
48. Health IMS. Global pharmaceutical sales by region - 2007. (Accessed January 30, 2009, at http://www.imshealth.com/deployedfiles/imshealth/Global/ Content/StaticFile/Top-Line-Data/GlobalSalesbyRegion.pdf.
49. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
50. Braman SS. The global burden of asthma. Chest 2006; 130:Suppl:4S-12S.
51. FDA Cardiovascular & Renal Drugs Advisory Committee. 2007 Meeting documents. (Accessed January 30, 2009, at http://www.fda.gov/ohrms/dockets/ac/ 07/transcripts/2007-4327t-02-part2.pdf.
52. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003;4:937-47. [Erratum, Nat Rev Genet 2004;5:76.]
53. Larson HN, Zhou J, Chen Z, Stamler JS, Weiner H, Hurley TD. Structural and functional consequences of coenzyme binding to the inactive Asian variant of mitochondrial aldehyde de- hydrogenase: roles of residues 475 and 487. J Biol Chem 2007; 282:12940-50.
54. Seitz HK, Matsuzaki S, Yokoyama A, Homann N, Väkeväinen S, Wang XD. Alcohol and cancer. Alcohol Clin Exp Res 2001;25:Suppl:137S-143S.
55. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline - guideline for Good Clinical Practice E6(R1). (Accessed January 30, 2009, at http://www.ich.org/LOB/media/MEDIA482.pdf.
56. Orr MS, Goodsaid F, Amur S, Rudman A, Frueh FW. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin Pharmacol Ther 2007;81:294-7.
57. The Central Institutional Review Board Initiative, National Cancer Institute home page. (Accessed January 30, 2009, at http://www.ncicirb.org/.
58. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities 2001;L121:34-44. (Accessed January 30, 2009, at http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121: 0034:0044:en:pdf.
59. Biomedical Research Alliance of New York home page. (Accessed January 30, 2009, at http://www.brany.com/.
60. Clinical Trials Transformation Initiative home page. (Accessed January 30, 2009, at http://www.trialstransformation.org/.
61. Drazen JM. Institutions, contracts, and academic freedom. N Engl J Med 2002;347:1362-3.
62. Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008;5:75-84.